| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $441,505 | 10 | 53 |
Sells | $284,028 | 9 | 47 |
| Topper James N | director | 5 | $191,988 | 0 | $0 | $191,988 |
| Parikh Asit | director | 4 | $150,433 | 0 | $0 | $150,433 |
| KARBE FRANK | director | 1 | $99,084 | 0 | $0 | $99,084 |
| Breedlove Robert Charles | Principal Accounting Officer | 0 | $0 | 3 | $26,804 | $-26,804 |
| Nabulsi Azmi | Chief Operating Officer | 0 | $0 | 2 | $60,901 | $-60,901 |
| Henderson Molly | CFO and CBO | 0 | $0 | 3 | $70,438 | $-70,438 |
| Curran Terrie | President and Chief Executive | 0 | $0 | 1 | $125,884 | $-125,884 |
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Over the last 12 months, insiders at Phathom Pharmaceuticals, Inc. have bought $441,505 and sold $284,028 worth of Phathom Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Phathom Pharmaceuticals, Inc. have bought $393,348 and sold $22.25M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Topper James N (director) — $191,988. Parikh Asit (director) — $150,433. KARBE FRANK (director) — $99,084.
The last purchase of 3,780 shares for transaction amount of $14,609 was made by Topper James N (director) on 2025‑05‑21.
| 2025-11-03 | Sale | Breedlove Robert Charles | Principal Accounting Officer | 524 0.0007% | $13.51 | $7,079 | +6.66% | |
| 2025-09-05 | Sale | Breedlove Robert Charles | Principal Accounting Officer | 461 0.0006% | $12.09 | $5,573 | +7.86% | |
| 2025-07-16 | Sale | Breedlove Robert Charles | Principal Accounting Officer | 1,692 0.0024% | $8.36 | $14,152 | +44.78% | |
| 2025-05-21 | Topper James N | director | 3,780 0.0054% | $3.86 | $14,609 | +192.44% | ||
| 2025-05-14 | Topper James N | director | 6,300 0.0092% | $3.32 | $20,919 | +240.00% | ||
| 2025-05-13 | Topper James N | director | 1,120 0.0015% | $3.16 | $3,543 | +233.08% | ||
| 2025-05-12 | Topper James N | director | 12,601 0.0174% | $3.04 | $38,301 | +249.21% | ||
| 2025-05-09 | Topper James N | director | 35,602 0.0523% | $3.22 | $114,616 | +250.00% | ||
| 2025-05-07 | Parikh Asit | director | 5,000 0.0072% | $2.40 | $11,985 | +356.88% | ||
| 2025-05-06 | Parikh Asit | director | 5,000 0.0078% | $2.60 | $13,000 | +356.25% | ||
| 2025-04-07 | Sale | Henderson Molly | CFO and CBO | 3,678 0.0049% | $4.55 | $16,740 | +113.14% | |
| 2025-03-13 | Parikh Asit | director | 10,000 0.015% | $4.42 | $44,200 | +130.21% | ||
| 2025-01-21 | Sale | Curran Terrie | President and Chief Executive | 19,109 0.0281% | $6.59 | $125,884 | +30.19% | |
| 2025-01-21 | Sale | Nabulsi Azmi | Chief Operating Officer | 7,886 0.0116% | $6.59 | $51,957 | +30.19% | |
| 2025-01-21 | Sale | Henderson Molly | CFO and CBO | 6,583 0.0097% | $6.59 | $43,371 | +30.19% | |
| 2024-12-19 | Sale | Nabulsi Azmi | Chief Operating Officer | 1,118 0.0017% | $8.00 | $8,944 | +9.21% | |
| 2024-12-19 | Sale | Henderson Molly | CFO and CBO | 1,291 0.0019% | $8.00 | $10,328 | +9.21% | |
| 2024-12-13 | Parikh Asit | director | 10,000 0.0149% | $8.12 | $81,248 | +6.08% | ||
| 2024-12-13 | KARBE FRANK | director | 12,500 0.0182% | $7.93 | $99,084 | +6.08% | ||
| 2024-07-15 | Sale | Curran Terrie | President and Chief Executive | 33,848 0.0663% | $11.72 | $396,699 | -30.90% |
| Curran Terrie | President and Chief Executive | 360465 0.5067% | $5.37M | 2 | 7 | +28.42% |
| Nabulsi Azmi | Chief Operating Officer | 233390 0.3281% | $3.48M | 2 | 16 | +23.07% |
| Parikh Asit | director | 95500 0.1343% | $1.42M | 11 | 0 | +32.4% |
| Henderson Molly | CFO and CBO | 89868 0.1263% | $1.34M | 1 | 13 | |
| Topper James N | director | 59403 0.0835% | $885,104.70 | 5 | 0 | |
| KARBE FRANK | director | 57000 0.0801% | $849,300.00 | 1 | 0 | |
| Breedlove Robert Charles | Principal Accounting Officer | 47407 0.0666% | $706,364.30 | 0 | 3 | |
| Frazier Life Sciences IX, L.P. | 10 percent owner | 7284269 10.2401% | $108.54M | 1 | 0 | +47.21% |
| TAKEDA PHARMACEUTICAL CO LTD | 10 percent owner | 3755583 5.2795% | $55.96M | 0 | 36 | |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 3115008 4.379% | $46.41M | 3 | 1 | +53.57% |
| Edwards Jonathan S. | director | 2019877 2.8395% | $30.1M | 1 | 0 | +47.21% |
| Socks David A | director | 1211346 1.7029% | $18.05M | 0 | 24 | |
| COLA MICHAEL F | director | 9798 0.0138% | $145,990.20 | 1 | 0 | +47.21% |
$8,217,280 | 112 | 46.33% | $1.1B | |
$607,159,124 | 92 | 3.55% | $1.11B | |
$61,783,526 | 37 | 18.57% | $1.16B | |
$150,196,329 | 28 | -8.09% | $1.07B | |
$7,598,498 | 27 | 34.68% | $989.32M | |
$103,156,698 | 27 | 19.10% | $1.12B | |
Phathom Pharmaceuticals, Inc. (PHAT) | $49,750,490 | 17 | 37.19% | $1.06B |
$276,750,010 | 16 | -7.95% | $1.16B | |
$18,336,420 | 12 | 24.03% | $1.06B | |
$49,967,154 | 11 | 62.08% | $1.14B | |
$11,541,901 | 10 | 8.07% | $1.01B | |
$5,794,001 | 10 | 23.26% | $996.4M | |
$1,580,951 | 9 | -14.18% | $1.08B | |
$160,798,946 | 8 | -3.92% | $997.23M | |
$46,235,722 | 6 | -31.77% | $989.19M | |
$21,792,890 | 6 | 75.72% | $981.93M | |
$19,420,853 | 5 | 4.35% | $1.02B | |
$45,070 | 4 | 10.31% | $982.19M | |
$33,624,000 | 2 | -50.37% | $1.03B |
| Increased Positions | 73 | +65.18% | 8M | +13.98% |
| Decreased Positions | 40 | -35.71% | 3M | -5.36% |
| New Positions | 26 | New | 2M | New |
| Sold Out Positions | 10 | Sold Out | 494,312 | Sold Out |
| Total Postitions | 145 | +29.46% | 62M | +8.62% |
| Frazier Life Sciences Management, L.P. | $181,761.00 | 17.56% | 12.47M | 0 | 0% | 2025-09-30 |
| Medicxi Ventures Management (Jersey) Ltd | $108,833.00 | 10.51% | 7.46M | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $74,088.00 | 7.16% | 5.08M | +3M | +125.79% | 2025-09-30 |
| Invesco Ltd. | $56,351.00 | 5.44% | 3.86M | -275,101 | -6.64% | 2025-09-30 |
| Carlyle Group Inc. | $50,983.00 | 4.93% | 3.5M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $49,606.00 | 4.79% | 3.4M | +86,976 | +2.62% | 2025-09-30 |
| Vanguard Group Inc | $46,883.00 | 4.53% | 3.22M | +428,261 | +15.37% | 2025-09-30 |
| Ensign Peak Advisors, Inc | $36,499.00 | 3.53% | 2.5M | -16,628 | -0.66% | 2025-09-30 |
| Nea Management Company, Llc | $28,579.00 | 2.76% | 1.96M | 0 | 0% | 2025-09-30 |
| 683 Capital Management, Llc | $26,541.00 | 2.56% | 1.82M | -284,620 | -13.52% | 2025-09-30 |